
RNTX
Healthcare · Biotechnology · $47.6M market cap
$0.5521-0.01 (-1.4%)Nov 13, 4:09 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +71.4% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2026 | Time not confirmed | -0.10 | — | — |
| Aug 14, 2026 | Before the open | -0.27 | -0.10 | +63.0% |
| May 15, 2026 | Before the open | -0.49 | -0.19 | +61.2% |
| Nov 14, 2025 | Before the open | -0.24 | -0.21 | +12.5% |
| Aug 14, 2025 | After the close | -0.22 | -0.28 | -27.3% |
| May 15, 2025 | After the close | -0.21 | -0.25 | -19.0% |
| Nov 14, 2024 | After the close | -0.35 | -0.27 | +22.9% |
| Aug 14, 2024 | After the close | -0.42 | -0.45 | -7.1% |
| May 15, 2024 | After the close | -1.02 | -0.86 | +15.7% |
| Oct 13, 2023 | After the close | -0.20 | -0.40 | -100.0% |
| Aug 8, 2023 | Time not confirmed | — | -0.39 | — |
| May 8, 2023 | Before the open | -0.60 | -1.05 | -75.0% |
| Mar 20, 2023 | Time not confirmed | -1.34 | -1.00 |
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a…
| +25.4% |
| Nov 1, 2022 | Before the open | -1.60 | -1.40 | +12.5% |
| Aug 15, 2022 | After the close | -1.90 | -1.80 | +5.3% |
| May 5, 2022 | After the close | -1.60 | -1.80 | -12.5% |
| Mar 28, 2022 | Time not confirmed | -0.08 | -0.08 | 0.0% |
| Nov 12, 2021 | Before the open | -1.40 | -1.40 | 0.0% |
| Aug 11, 2021 | After the close | -1.40 | -1.20 | +14.3% |
| May 11, 2021 | After the close | -1.10 | -1.60 | -45.5% |
| Mar 24, 2021 | Time not confirmed | -0.13 | -0.12 | +5.8% |
| Nov 12, 2020 | After the close | -2.75 | -2.60 | +5.5% |
| Aug 5, 2020 | After the close | -3.73 | -2.80 | +24.9% |
| May 11, 2020 | Before the open | -4.20 | -4.80 | -14.3% |
| Mar 30, 2020 | Time not confirmed | -0.27 | -0.26 | +3.7% |
| Nov 7, 2019 | Before the open | -4.75 | -5.60 | -17.9% |
| Aug 6, 2019 | After the close | -4.45 | -5.20 | -16.9% |
| May 8, 2019 | After the close | -7.75 | -9.80 | -26.5% |
| Nov 7, 2018 | After the close | -11.10 | -10.00 | +9.9% |
| Aug 7, 2018 | After the close | -10.40 | -12.80 | -23.1% |
| May 9, 2018 | After the close | -10.00 | -10.40 | -4.0% |